Advanced Medical Optics Awarded $213.9 Million in Infringement Case Against Alcon

District Court Judge Trebles Damages and Upholds Jury's Findings

of Infringement and Willfulness



19 Dec, 2005, 00:00 ET from Advanced Medical Optics, Inc.

    SANTA ANA, Calif., Dec. 19 /PRNewswire-FirstCall/ -- Advanced Medical
 Optics, Inc. (AMO) (NYSE:   EYE) announced today that a judge has upheld a May
 2005 jury decision and awarded AMO $213.9 million in damages resulting from
 willful infringement by Alcon Manufacturing, Ltd. and Alcon Laboratories, Inc.
 (NYSE:   ACL) of two AMO patents for phacoemulsification equipment used in
 cataract surgery.
     (LOGO:  http://www.newscom.com/cgi-bin/prnh/20050324/AMOLOGO )
     The judge for the United States District Court for the District of
 Delaware concluded that "the jury was presented with clear and convincing
 evidence that Alcon intentionally copied" the occlusion mode and the fluidics
 system from AMO's Sovereign(R) machine. The judge further added, "I agree that
 this is an exceptional case, that the damages award should be trebled, and
 that reasonable attorneys fees should be awarded."
     The judge granted AMO a permanent injunction, but that injunction has been
 stayed pending appeal. Once in effect, the injunction will prohibit Alcon from
 selling equipment with the features that infringed AMO's patents. The judge
 also required Alcon to post a $1.8 million bond on the injunction pending
 appeal.
     "The judge's decision validates the importance of AMO's commitment to
 develop superior technology that offers unique benefits to surgeons and the
 patients they serve," said AMO President and CEO Jim Mazzo. "We will continue
 to take all necessary steps to protect and defend the investment we make in
 technology on behalf of our customers and stockholders."
     In May 2005, a jury awarded AMO $94.8 million in damages, reflecting lost
 profits and reasonable royalty fees through February 2005. Subsequently, the
 judge ruled that AMO did not sufficiently mark its patents on the equipment
 and reduced the award to $71.3 million. This revised amount was trebled,
 resulting in total damages of $213.9 million for this period. The final
 judgment will include damages on infringing products sold by Alcon after March
 2005, plus pre-judgment interest. Alcon has 30 days to file an appeal of the
 judgment and thereafter may seek a stay of payment of the judgment upon
 posting of a sufficient bond.
     AMO originally filed a complaint in the U.S. District Court for the
 District of Delaware against Alcon Manufacturing, Ltd. and Alcon Laboratories,
 Inc. on December 3, 2003 for infringement of U.S. Patent Nos. 5,700,240
 relating to occlusion mode technology and 6,059,765 relating to a fluidics
 management system.
 
     About Advanced Medical Optics (AMO)
     AMO is a global medical device leader focused on the discovery and
 delivery of innovative vision technologies that optimize the quality of life
 for people of all ages. Products in the ophthalmic surgical line include
 intraocular lenses, laser vision correction systems, phacoemulsification
 systems, viscoelastics, microkeratomes and related products used in cataract
 and refractive surgery. AMO owns or has the rights to such ophthalmic surgical
 product brands as ReZoom(TM), Clariflex(R), Array(R), Sensar(R), CeeOn(R),
 Tecnis(R) and Verisyse(TM) intraocular lenses, STAR S4 IR(TM) laser vision
 correction system, WaveScan Wavefront(R) System, CustomVue(TM) procedure,
 Sovereign(R) and Sovereign(R) Compact(TM) phacoemulsification systems with
 WhiteStar(R) technology, Amadeus(TM) and Amadeus(TM) II microkeratomes,
 Healon(R) viscoelastics, and the Baerveldt(R) glaucoma shunt. Products in the
 contact lens care line include disinfecting solutions, daily cleaners,
 enzymatic cleaners and lens rewetting drops. Among the contact lens care
 product brands the company possesses are COMPLETE(R) Moisture PLUS(TM),
 COMPLETE(R) Blink-N-Clean(R), Consept(R)F, Consept(R) 1 Step, Oxysept(R) 1
 Step, UltraCare(R), Ultrazyme(R), Total Care(TM) and blink(TM) branded
 products.  Amadeus is a licensed product of, and a trademark of, SIS, Ltd. AMO
 is based in Santa Ana, California, and employs approximately 3,500 worldwide.
 The company has operations in 24 countries and markets products in
 approximately 60 countries.  For more information, visit the company's Web
 site at http://www.amo-inc.com.
 
     Forward Looking Statements
     This press release contains forward-looking statements. Any statements in
 this press release that refer to AMO's estimated or anticipated future results
 are forward-looking statements. All forward-looking statements in this press
 release reflect AMO's current analysis of existing trends and information and
 represent AMO's judgment only as of the date of this press release. Actual
 results may differ from current expectations based on a number of factors
 affecting AMO's business, including but not limited to a possible appeal of
 the award, collectability of the damages awarded, uncertainties relating to
 permanent injunctive relief, and unpredictable competitive, regulatory and
 market conditions. Therefore, the reader is cautioned not to rely on these
 forward-looking statements. AMO disclaims any intent or obligation to update
 these forward-looking statements.
     Additional information concerning these and other risk factors may be
 found in AMO's public periodic filings with the Securities and Exchange
 Commission, including the discussion under the heading "Certain Factors and
 Trends Affecting AMO and its Businesses" in AMO's 2004 Form 10-K.  Copies of
 press releases and additional information about AMO are available at
 http://www.amo-inc.com, or you can contact the AMO Investor Relations
 Department by calling 714-247-8348.
 
     Advanced Medical Optics, Inc.
     Investors:
     Sheree Aronson
     (714) 247-8290
     sheree.aronson@amo-inc.com
 
     Media:
     Steve Chesterman
     (714) 247-8711
     steve.chesterman@amo-inc.com
 
 

SOURCE Advanced Medical Optics, Inc.
    SANTA ANA, Calif., Dec. 19 /PRNewswire-FirstCall/ -- Advanced Medical
 Optics, Inc. (AMO) (NYSE:   EYE) announced today that a judge has upheld a May
 2005 jury decision and awarded AMO $213.9 million in damages resulting from
 willful infringement by Alcon Manufacturing, Ltd. and Alcon Laboratories, Inc.
 (NYSE:   ACL) of two AMO patents for phacoemulsification equipment used in
 cataract surgery.
     (LOGO:  http://www.newscom.com/cgi-bin/prnh/20050324/AMOLOGO )
     The judge for the United States District Court for the District of
 Delaware concluded that "the jury was presented with clear and convincing
 evidence that Alcon intentionally copied" the occlusion mode and the fluidics
 system from AMO's Sovereign(R) machine. The judge further added, "I agree that
 this is an exceptional case, that the damages award should be trebled, and
 that reasonable attorneys fees should be awarded."
     The judge granted AMO a permanent injunction, but that injunction has been
 stayed pending appeal. Once in effect, the injunction will prohibit Alcon from
 selling equipment with the features that infringed AMO's patents. The judge
 also required Alcon to post a $1.8 million bond on the injunction pending
 appeal.
     "The judge's decision validates the importance of AMO's commitment to
 develop superior technology that offers unique benefits to surgeons and the
 patients they serve," said AMO President and CEO Jim Mazzo. "We will continue
 to take all necessary steps to protect and defend the investment we make in
 technology on behalf of our customers and stockholders."
     In May 2005, a jury awarded AMO $94.8 million in damages, reflecting lost
 profits and reasonable royalty fees through February 2005. Subsequently, the
 judge ruled that AMO did not sufficiently mark its patents on the equipment
 and reduced the award to $71.3 million. This revised amount was trebled,
 resulting in total damages of $213.9 million for this period. The final
 judgment will include damages on infringing products sold by Alcon after March
 2005, plus pre-judgment interest. Alcon has 30 days to file an appeal of the
 judgment and thereafter may seek a stay of payment of the judgment upon
 posting of a sufficient bond.
     AMO originally filed a complaint in the U.S. District Court for the
 District of Delaware against Alcon Manufacturing, Ltd. and Alcon Laboratories,
 Inc. on December 3, 2003 for infringement of U.S. Patent Nos. 5,700,240
 relating to occlusion mode technology and 6,059,765 relating to a fluidics
 management system.
 
     About Advanced Medical Optics (AMO)
     AMO is a global medical device leader focused on the discovery and
 delivery of innovative vision technologies that optimize the quality of life
 for people of all ages. Products in the ophthalmic surgical line include
 intraocular lenses, laser vision correction systems, phacoemulsification
 systems, viscoelastics, microkeratomes and related products used in cataract
 and refractive surgery. AMO owns or has the rights to such ophthalmic surgical
 product brands as ReZoom(TM), Clariflex(R), Array(R), Sensar(R), CeeOn(R),
 Tecnis(R) and Verisyse(TM) intraocular lenses, STAR S4 IR(TM) laser vision
 correction system, WaveScan Wavefront(R) System, CustomVue(TM) procedure,
 Sovereign(R) and Sovereign(R) Compact(TM) phacoemulsification systems with
 WhiteStar(R) technology, Amadeus(TM) and Amadeus(TM) II microkeratomes,
 Healon(R) viscoelastics, and the Baerveldt(R) glaucoma shunt. Products in the
 contact lens care line include disinfecting solutions, daily cleaners,
 enzymatic cleaners and lens rewetting drops. Among the contact lens care
 product brands the company possesses are COMPLETE(R) Moisture PLUS(TM),
 COMPLETE(R) Blink-N-Clean(R), Consept(R)F, Consept(R) 1 Step, Oxysept(R) 1
 Step, UltraCare(R), Ultrazyme(R), Total Care(TM) and blink(TM) branded
 products.  Amadeus is a licensed product of, and a trademark of, SIS, Ltd. AMO
 is based in Santa Ana, California, and employs approximately 3,500 worldwide.
 The company has operations in 24 countries and markets products in
 approximately 60 countries.  For more information, visit the company's Web
 site at http://www.amo-inc.com.
 
     Forward Looking Statements
     This press release contains forward-looking statements. Any statements in
 this press release that refer to AMO's estimated or anticipated future results
 are forward-looking statements. All forward-looking statements in this press
 release reflect AMO's current analysis of existing trends and information and
 represent AMO's judgment only as of the date of this press release. Actual
 results may differ from current expectations based on a number of factors
 affecting AMO's business, including but not limited to a possible appeal of
 the award, collectability of the damages awarded, uncertainties relating to
 permanent injunctive relief, and unpredictable competitive, regulatory and
 market conditions. Therefore, the reader is cautioned not to rely on these
 forward-looking statements. AMO disclaims any intent or obligation to update
 these forward-looking statements.
     Additional information concerning these and other risk factors may be
 found in AMO's public periodic filings with the Securities and Exchange
 Commission, including the discussion under the heading "Certain Factors and
 Trends Affecting AMO and its Businesses" in AMO's 2004 Form 10-K.  Copies of
 press releases and additional information about AMO are available at
 http://www.amo-inc.com, or you can contact the AMO Investor Relations
 Department by calling 714-247-8348.
 
     Advanced Medical Optics, Inc.
     Investors:
     Sheree Aronson
     (714) 247-8290
     sheree.aronson@amo-inc.com
 
     Media:
     Steve Chesterman
     (714) 247-8711
     steve.chesterman@amo-inc.com
 
 SOURCE  Advanced Medical Optics, Inc.